Assembly Biosciences (ASMB) Projected to Post Earnings on Thursday

Assembly Biosciences (NASDAQ:ASMB) is projected to release its Q4 2025 results before the market opens on Thursday, March 19th. Analysts expect Assembly Biosciences to post earnings of ($0.51) per share and revenue of $7.42 million for the quarter. Interested persons can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Friday, March 20, 2026 at 4:00 PM ET.

Assembly Biosciences Price Performance

NASDAQ ASMB opened at $29.21 on Thursday. The stock’s 50-day moving average is $28.73 and its 200-day moving average is $29.48. Assembly Biosciences has a one year low of $7.75 and a one year high of $39.71. The firm has a market cap of $462.10 million, a P/E ratio of -6.10 and a beta of 1.11.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Assembly Biosciences in a report on Wednesday, January 21st. Mizuho set a $40.00 price target on Assembly Biosciences and gave the company an “outperform” rating in a report on Thursday, November 20th. Finally, HC Wainwright reiterated a “buy” rating and set a $50.00 price objective on shares of Assembly Biosciences in a report on Monday, December 22nd. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $41.75.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. Virtus Investment Advisers LLC acquired a new stake in shares of Assembly Biosciences in the 4th quarter valued at approximately $251,000. Susquehanna Portfolio Strategies LLC bought a new stake in shares of Assembly Biosciences in the 4th quarter valued at about $473,000. Superstring Capital Management LP acquired a new stake in Assembly Biosciences in the 4th quarter valued at about $2,220,000. Millennium Management LLC grew its holdings in Assembly Biosciences by 354.6% during the fourth quarter. Millennium Management LLC now owns 98,221 shares of the biopharmaceutical company’s stock worth $3,340,000 after purchasing an additional 76,613 shares during the period. Finally, Janus Henderson Group PLC raised its stake in Assembly Biosciences by 11.3% in the fourth quarter. Janus Henderson Group PLC now owns 837,925 shares of the biopharmaceutical company’s stock valued at $28,540,000 after buying an additional 85,299 shares during the period. Institutional investors and hedge funds own 19.92% of the company’s stock.

About Assembly Biosciences

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.